MEDIROM Healthcare Technologies
MRM
1 hedge funds and large institutions have $25 invested in MEDIROM Healthcare Technologies in 2023 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
0.04% less ownership
Funds ownership: 0.04% → 0% (-0.04%)
100% less capital invested
Capital invested by funds: $8.74K → $25 (-$8.72K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$11.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $25 | -$11.7K | -1,935 | -100% |
|
MRM Hedge Fund Activity: Q1 2023 in Review
1 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in MEDIROM Healthcare Technologies (MRM) for Q1 2023, worth a combined $25 — down 100% from $8.74K a quarter earlier.
Fund positioning in MRM was balanced in Q1 2023: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $11.7K.
- 1 institutional investor held MEDIROM Healthcare Technologies (MRM) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $25 of MEDIROM Healthcare Technologies stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new MEDIROM Healthcare Technologies positions in Q1 2023 and 0 closed out.
- The largest MEDIROM Healthcare Technologies seller in Q1 2023 was UBS Group, an estimated $11.7K sold.
Based on aggregated 13F filings for Q1 2023.